Budget impact and cost per responder analysis of upadacitinib for the treatment of moderate to severe atopic dermatitis from the perspective of the social security and the private sector in Argentina.
Natalia EspinolaFederico Rodriguez CairoliCarlos Rojas-RoquePaula Carolina LunaDiego KanevskyValeria MigliazzaAndrés Pichon-RivierePublished in: Expert review of pharmacoeconomics & outcomes research (2024)
The introduction of upadacitinib in MS-AD treatment was associated with modest savings for the social security and private payer budget in Argentina.